Online citations, reference lists, and bibliographies.
← Back to Search

Can The Pharmaceutical Industry Reduce Attrition Rates?

I. Kola, John L. Landis
Published 2004 · Business, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The pharmaceutical industry faces considerable challenges, both politically and fiscally. Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny. In the United States, drug costs are also the subject of intense political discourse. This article deals with the fiscal pressures that face the industry from the perspective of R&D. What impinges on productivity? How can we improve current reduced R&D productivity?
This paper references



This paper is referenced by
10.1016/B978-0-12-819376-1.00011-1
Bioreactors and microphysiological systems for adipose-based pharmacologic screening
Mallory D. Griffin (2022)
10.1016/j.technovation.2021.102363
Absorbing knowledge from an emerging field: The role of interfacing by proponents in big pharma
Angelo K.S. Romasanta (2021)
10.1016/j.xphs.2021.01.020
Prediction of total drug clearance in humans using animal data: proposal of a multimodal learning method based on deep learning.
Hiroaki Iwata (2021)
10.1007/978-981-15-5534-3_17
Pharmaceutical Industry, Academia, Regulatory Authorities and End User Collaboration in Successful Drug Discovery and Development
R. Poduri (2021)
10.1186/s13062-020-00288-x
An ensemble learning approach for modeling the systems biology of drug-induced injury
J. Aguirre-Plans (2021)
10.1016/j.stemcr.2021.08.004
Challenging the pipeline
P. Loskill (2021)
10.5220/0010267701520159
Virtual Screening of Pharmaceutical Compounds with hERG Inhibitory Activity (Cardiotoxicity) using Ensemble Learning
A. Sarkar (2021)
10.1016/j.bbrc.2021.03.039
Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
Seul-Gi Lee (2021)
10.1108/IJPPM-09-2020-0472
Application of tools and techniques of quality by design in pharmaceutical process
E. V. Gijo (2021)
10.1002/mus.27360
Creating stem cell‐derived neuromuscular junctions in vitro
Shawn M. Luttrell (2021)
10.1016/j.radonc.2021.02.024
Value of functional in-vivo endpoints in preclinical radiation research.
Berit Kummer (2021)
10.4018/IJQSPR.2021010101
The Position of ADME Predictions in Multi-Objective QSAR
A. Tsantili-Kakoulidou (2021)
10.3390/molecules26185629
The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes
Douglas B Kell (2021)
10.1007/978-981-33-6064-8_20
The Application of Mass Spectrometry in Drug Metabolism and Pharmacokinetics.
Ji-Yoon Lee (2021)
10.1039/d0ra09995c
The importance of intramolecular hydrogen bonds on the translocation of the small drug piracetam through a lipid bilayer
J. Coimbra (2021)
10.1101/2021.05.03.442516
A spatially resolved mechanistic growth law for cancer drug development predicting tumour growing fractions
Adam Nasim (2021)
10.1002/aur.2512
Assessment of medical morbidities in a rhesus monkey model of naturally occurring low sociality
A. Myers (2021)
10.1016/B978-0-12-821972-0.00013-7
Human in vitro disease models to aid pathway and target discovery for neurological disorders
Bhavana Muralidharan (2021)
10.1007/s11912-021-01023-z
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs
Nalinie Joharatnam-Hogan (2021)
10.1080/00498254.2021.1918800
A high-throughput cell-based gaussia luciferase reporter assay for measurement of CYP1A1, CYP2B6, and CYP3A4 induction
Han Li (2021)
10.1016/j.jksus.2020.101313
Molecular structure simulation of (E)-2-(butan-2-ylidene) hydrazinecarbothioamide using the DFT approach, and antioxidant potential assessment of its complexes
Tahmeena Khan (2021)
10.1093/nar/gkab255
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
Guoli Xiong (2021)
10.1016/B978-0-12-822878-4.00003-1
Nanotheranostics and biocompatibility
I. Sharma (2021)
10.3390/molecules26133800
Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs
S. Daley (2021)
10.1124/dmd.121.000476
Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation
M. Parvez (2021)
10.1002/adhm.202100131
Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Produce Distinct Neural 3D In Vitro Models Depending on Alginate/Gellan Gum/Laminin Hydrogel Blend Properties.
Julia Kapr (2021)
10.1287/MNSC.2019.3530
Rushed Innovation: Evidence from Drug Licensing
Manuel Hermosilla (2021)
10.1016/BS.PMCH.2021.01.002
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
M. Maneiro (2021)
10.5465/ambpp.2021.12619abstract
The Role of Science in Drug Development Decisions
L. Colen (2021)
10.3389/fnins.2021.652403
Translational Block in Stroke: A Constructive and “Out-of-the-Box” Reappraisal
A. Lourbopoulos (2021)
10.1016/B978-0-12-820546-4.00014-3
ADMET tools: Prediction and assessment of chemical ADMET properties of NCEs
O. Silakari (2021)
10.1101/2021.05.06.443046
Host bioenergetic parameters reveal cytotoxicity of anti-tuberculosis drugs undetected using conventional viability assays
Bridgette M. Cumming (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar